Roche Holding AG (RHHBF)
| Market Cap | 230.53B |
| Revenue (ttm) | 67.42B |
| Net Income (ttm) | 11.82B |
| Shares Out | n/a |
| EPS (ttm) | 14.73 |
| PE Ratio | 19.51 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 100 |
| Open | 290.25 |
| Previous Close | 310.00 |
| Day's Range | 290.25 - 317.20 |
| 52-Week Range | 243.42 - 368.43 |
| Beta | 0.15 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jan 31, 2025 |
About Roche Holding AG
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, d... [Read more]
Financial Performance
In 2023, Roche Holding AG's revenue was 60.44 billion, a decrease of -8.16% compared to the previous year's 65.81 billion. Earnings were 11.50 billion, a decrease of -7.43%.
Financial numbers in CHF Financial StatementsNews
FDA accepts supplemental Biologics License Application for Roche's Columvi combination for people with relapsed or refractory diffuse large B-cell lymphoma
Basel, 5 December 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA...
FDA Accepts Supplemental Biologics License Application for Genentech's Columvi Combination for People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has accepted the com...
Gypto Pharma and Roche celebrate the successful completion of the first phase of transferring biotechnology and manufacturing a biologic drug to treat liver cancer using Swiss technology
This milestone marks a significant contribution to Egypt's transformation from a technology user into a technology leader
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?
Outlook Therapeutics Inc. (NASDAQ: OTLK) revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in wet AMD patients . In the NORSE EIGHT trial, ONS...
Poseida shares triple on Tuesday, boosted by Roche collaboration
Shares of Poseida Therapeutics Inc (NASDAQ: PSTX) more than tripled this morning after Roche Holding (SWX: ROG) said it will buy the clinical-stage biopharmaceutical company for about $1.5 billion. Ro...
Nasdaq Rises 100 Points; Abercrombie & Fitch Shares Fall After Q3 Results
U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 100 points on Tuesday. The Dow traded down 0.26% to 44,621.76 while the NASDAQ rose 0.52% to 19,154.38. The S&...
Poseida Therapeutics (PSTX) Soars Over 223% on Roche Acquisition News
Poseida Therapeutics (PSTX) Soars Over 223% on Roche Acquisition News
Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details
On Tuesday, Roche Holdings AG (OTC: RHHBY) agreed to acquire Poseida Therapeutics, Inc. (NASDAQ: PSTX) for an equity value of approximately $1.5 billion on a fully diluted basis . The deal considera...
Roche's Proposed Acquisition Of Poseida Therapeutics Poised To Establish New Core Capability In Cell Therapy For Cancer And Autoimmune Diseases: Details
On Tuesday, Roche Holdings AG RHHBY agreed to acquire Poseida Therapeutics, Inc. PSTX for an equity value of approximately $1.5 billion on a fully diluted basis.
Roche to Acquire Poseida Therapeutics (PSTX) for $1.5 Billion
Roche to Acquire Poseida Therapeutics (PSTX) for $1.5 Billion
Roche anti-TIGIT therapy fails to extend survival in late-stage lung cancer trial
Why Poseida Therapeutics Shares Are Trading Higher By 219%; Here Are 20 Stocks Moving Premarket
Shares of Poseida Therapeutics, Inc . (NASDAQ: PSTX) rose sharply in today's pre-market trading after the company agreed to be acquired by Roche in a $1.5 billion deal. Poseida Therapeutics shares ju...
Poseida Therapeutics skyrockets 218% on $1.5B Roche acquisition offer
Roche to Acquire Poseida Therapeutics for Up to $1.5 Billion
Roche to Acquire Poseida Therapeutics for Up to $1.5 Billion
Best Buy, HP And 3 Stocks To Watch Heading Into Tuesday
With U.S. stock futures trading slightly higher this morning on Tuesday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Best Buy Co., Inc . (NYSE: BBY) to r...
Roche to Acquire Poseida Therapeutics in $1 Billion Deal
Roche to Acquire Poseida Therapeutics in $1 Billion Deal
Roche to Acquire Poseida Therapeutics in a Deal Worth Up to $1.5 Billion
Roche records setback in phase III study of two lung cancer drugs
A Roche study into using a combination of tiragolumab and tecentriq to treat a form of lung cancer in a phase III trial did not achieve the desired success, the Swiss pharmaceuticals maker said on Tue...
Roche to acquire US-based Poseida Therapeutics
Roche will acquire California-based biopharmafirm Poseida Therapeutics for $9 per share at closing, for a total equity value of $1 billion, the Swiss company said on Tuesday.
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies
Basel, 26 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has entered into a definitive merger agreement to acquire Poseida Therapeutics, Inc. (“Poseida”, NASDAQ: PSTX), a p...
Poseida Therapeutics, Inc. Announces Agreement to be Acquired by Roche Holdings, Inc.
Poseida stockholders to receive up to $13.00 per share in cash, comprised of $9.00 per share in cash at closing and a non-tradeable contingent value right (CVR) to receive up to an aggregate of $4.00 ...
Roche reports update on Phase III SKYSCRAPER-01 study results
Basel, 26 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) reports an update on the phase III SKYSCRAPER-01 study, evaluating tiragolumab combined with Tecentriq® (atezolizumab) compared to Tecentri...
Genentech Reports Update on Phase III SKYSCRAPER-01 Study Results
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), reports an update on the Phase III SKYSCRAPER-01 study, evaluating tiragolumab combin...
Roche receives FDA approval for first companion diagnostic to identify patients with biliary tract cancer eligible for HER2-targeted treatment with ZIIHERA
The PATHWAY HER2 (4B5) test helps to identify patients with previously-treated, unresectable or metastatic HER2-positive biliary tract cancer (BTC) who may be eligible for treatment with ZIIHERA. Ther...
Roche Canada Announces New Informatics Jobs in Ontario's Life Sciences Sector
These jobs will propel the province towards being a global leader in biomanufacturing and life sciences MISSISSAUGA, ON , Nov. 19, 2024 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to a...